Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
January 6, 2016
PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer
Jaekwang Jeong, Joshua N VanHouten, Pamela Dann, et al.
Pigment Cell & Melanoma Research
|
April 10, 2015
The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors
Casey G Langdon, Matthew A Held, James T Platt, et al.
Oncotarget
|
October 21, 2015
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
Casey G Langdon, Norbert Wiedemann, Matthew A Held, et al.
Cancer Discovery
|
December 15, 2012
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening
Matthew A Held, Casey G Langdon, James T Platt, et al.
Cancer Investigation
|
October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
Shanu Modi, Michael P DiGiovanna, Zhao Lu, et al.
Cancer Research
|
July 13, 2014
Enhancing reproducibility in cancer drug screening: how do we move forward?
Christos Hatzis, Philippe L Bedard, Nicolai J Birkbak, et al.
Molecular Cancer Therapeutics
|
March 16, 2017
Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Casey G Langdon, James T Platt, Robert E Means, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
Michael P DiGiovanna, David F Stern, Susan Edgerton, et al.
Cancer Research
|
February 26, 2015
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
Marzia Scortegagna, Eric Lau, Tongwu Zhang, et al.
The Journal of Investigative Dermatology
|
April 15, 2006
Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar
Jack L Arbiser, Baskaran Govindarajan, Traci E Battle, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
Proceedings of the National Academy of Sciences of the United States of America
|
January 6, 2016
PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer
Jaekwang Jeong, Joshua N VanHouten, Pamela Dann, et al.
Pigment Cell & Melanoma Research
|
April 10, 2015
The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors
Casey G Langdon, Matthew A Held, James T Platt, et al.
Oncotarget
|
October 21, 2015
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
Casey G Langdon, Norbert Wiedemann, Matthew A Held, et al.
Cancer Discovery
|
December 15, 2012
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening
Matthew A Held, Casey G Langdon, James T Platt, et al.
Cancer Investigation
|
October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
Shanu Modi, Michael P DiGiovanna, Zhao Lu, et al.
Cancer Research
|
July 13, 2014
Enhancing reproducibility in cancer drug screening: how do we move forward?
Christos Hatzis, Philippe L Bedard, Nicolai J Birkbak, et al.
Molecular Cancer Therapeutics
|
March 16, 2017
Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Casey G Langdon, James T Platt, Robert E Means, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
Michael P DiGiovanna, David F Stern, Susan Edgerton, et al.
Cancer Research
|
February 26, 2015
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
Marzia Scortegagna, Eric Lau, Tongwu Zhang, et al.
The Journal of Investigative Dermatology
|
April 15, 2006
Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar
Jack L Arbiser, Baskaran Govindarajan, Traci E Battle, et al.
Page
of 8